Advertisement

Topics

NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment

02:50 EDT 17 Apr 2018 | BioMedReports - Blog

The study is a double-blind, placebo-controlled, single-dose, dose-escalation phase I clinical study to investigate the pharmacokinetics and safety/tolerability of KL1333 in 60 healthy subjects. All

Read more...

Original Article: NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment

NEXT ARTICLE

More From BioPortfolio on "NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...